Clinical trials present a new approach using immunotherapy

After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations. The results of two studies have been presented at the European Society for Medical Oncology (ESMO) conference in Madrid. The outcomes of these studies could revolutionize the landscape of bladder cancer treatment.

What is cancer immunotherapy?

KRAS-Targeted Therapy Doubles as Component of Immunotherapy - NCI

Clinical trial: New dual therapy could revolutionize treatment of urothelial and bladder cancers

The Cancer Research Institute and Parker Institute for Cancer Immunotherapy Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy - Cancer Research Institute

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations

Phase I Clinical Trial Using CAR-T for Glioblastoma to Begin at UNC Medical Center

Immunotherapy: Pushing the Frontier of Cancer Medicine

JCI - Progress on new vaccine strategies for the immunotherapy and prevention of cancer

Immunotherapeutics and Vaccine Research Initiative (IVRI)

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy - Parker Institute for Cancer Immunotherapy

LAG3: A Promising New Cancer Immunotherapy Target